Ginsenoside Rb1: The new treatment measure of myasthenia gravis

2016 ◽  
Vol 41 ◽  
pp. 136-143 ◽  
Author(s):  
Wei Chen ◽  
Qing-Fang Meng ◽  
Jun-Kang Sui ◽  
Yan-Jun Wang ◽  
Xiao-Li Li ◽  
...  
2012 ◽  
Vol 2012 ◽  
pp. 1-10 ◽  
Author(s):  
Annapurni Jayam Trouth ◽  
Alok Dabi ◽  
Noha Solieman ◽  
Mohankumar Kurukumbi ◽  
Janaki Kalyanam

Acquired myasthenia gravis is a relatively uncommon disorder, with prevalence rates that have increased to about 20 per 100,000 in the US population. This autoimmune disease is characterized by muscle weakness that fluctuates, worsening with exertion, and improving with rest. In about two-thirds of the patients, the involvement of extrinsic ocular muscle presents as the initial symptom, usually progressing to involve other bulbar muscles and limb musculature, resulting in generalized myasthenia gravis. Although the cause of the disorder is unknown, the role of circulating antibodies directed against the nicotinic acetylcholine receptor in its pathogenesis is well established. As this disorder is highly treatable, prompt recognition is crucial. During the past decade, significant progress has been made in our understanding of the disease, leading to new treatment modalities and a significant reduction in morbidity and mortality.


Drugs ◽  
1990 ◽  
Vol 39 (1) ◽  
pp. 66-73 ◽  
Author(s):  
C. W.H. Havard ◽  
V. Fonseca

2016 ◽  
Vol 22 ◽  
pp. 277-278
Author(s):  
Lima Lawrence ◽  
Aleida Rodriguez ◽  
Tahira Yasmeen ◽  
Erin Drever

VASA ◽  
2012 ◽  
Vol 41 (3) ◽  
pp. 163-176 ◽  
Author(s):  
Weidenhagen ◽  
Bombien ◽  
Meimarakis ◽  
Geisler ◽  
A. Koeppel

Open surgical repair of lesions of the descending thoracic aorta, such as aneurysm, dissection and traumatic rupture, has been the “state-of-the-art” treatment for many decades. However, in specialized cardiovascular centers, thoracic endovascular aortic repair and hybrid aortic procedures have been implemented as novel treatment options. The current clinical results show that these procedures can be performed with low morbidity and mortality rates. However, due to a lack of randomized trials, the level of reliability of these new treatment modalities remains a matter of discussion. Clinical decision-making is generally based on the experience of the vascular center as well as on individual factors, such as life expectancy, comorbidity, aneurysm aetiology, aortic diameter and morphology. This article will review and discuss recent publications of open surgical, hybrid thoracic aortic (in case of aortic arch involvement) and endovascular repair in complex pathologies of the descending thoracic aorta.


2000 ◽  
Author(s):  
S. S. Luthar ◽  
N. E. Suchman
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document